Joshua Fitch

HCPLive highlights key pediatric gastroenterology updates from NASPGHAN 2025, with continuing coverage to follow.

Data presented at NASPGHAN 2025 revealed odevixibat demonstrated sustained improvements in sleep and caregiver-reported QOL in patients with Alagille syndrome through 96 weeks.

Long-term analysis of the PEDFIC studies presented at NASPGHAN 2025 demonstrated sustained reductions in bile acids and pruritus with odevixibat in FIC1 deficiency.

At NASPGHAN 2025, investigators presented 52-week safety data from an ongoing phase 3 trial of linaclotide, the first approved treatment for patients aged 7 and older with IBS-C.

This preview of the 2025 NASPGHAN Annual Meeting highlights sessions and expert discussions on pediatric gastroenterology, hepatology, and nutrition covered by HCPLive.

Needle-free treatments, such as Neffy and FluMist, offer promising alternatives for children and adults with needle phobia, ensuring access to critical care.

The Contemporary Pediatrics Editor-in-Chief reviews the pharmacological breakthroughs and epidemiological setbacks that defined RSV in 2023.